{"id":"2-3-dideoxyinosine","safety":{"commonSideEffects":[{"rate":null,"effect":"Pancreatitis"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Lactic acidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ddI is a purine nucleoside analog that is phosphorylated intracellularly to its active form, ddATP, which competitively inhibits HIV reverse transcriptase and causes chain termination during viral DNA synthesis. This prevents the virus from integrating its genetic material into the host cell genome and replicating. It was one of the early antiretroviral agents developed for HIV treatment.","oneSentence":"2',3'-dideoxyinosine (ddI) is a nucleoside reverse transcriptase inhibitor that blocks HIV replication by inhibiting the enzyme responsible for converting viral RNA into DNA.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:56:30.042Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT00955968","phase":"PHASE4","title":"IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2010-01-01","conditions":"HIV Infection","enrollment":1653},{"nctId":"NCT00109590","phase":"PHASE2","title":"Reducing the Incidence of Nevirapine Resistance Mutations in Pregnant HIV Infected Women Who Receive Anti-HIV Drugs Prior to and After Giving Birth","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-06","conditions":"HIV Infections","enrollment":175},{"nctId":"NCT00016718","phase":"PHASE1, PHASE2","title":"Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-08","conditions":"HIV Infections","enrollment":43},{"nctId":"NCT00000710","phase":"PHASE1","title":"A Phase I Safety, Efficacy, and Pharmacokinetic Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Patients With AIDS or AIDS Related Complex","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":42},{"nctId":"NCT00001045","phase":"PHASE2","title":"Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients With No Symptoms of the Disease","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00001029","phase":"PHASE2","title":"A Comparison of Three Treatments for Advanced HIV Disease in Patients Who Have Received Nucleoside Therapy in the Past","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":654},{"nctId":"NCT00001063","phase":"PHASE2","title":"The Effectiveness of Three Drug Combinations in HIV-Infected Patients Who Have Taken Zidovudine for More Than 12 Weeks","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":200},{"nctId":"NCT00000969","phase":"NA","title":"A Prospective, Randomized, Open-Label, Comparative Trial of Dideoxyinosine (ddI) Versus Dideoxycytidine (ddC) in HIV-Infected Patients Who Are Intolerant of or Who Have Failed Zidovudine (AZT) Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":400},{"nctId":"NCT00000657","phase":"PHASE2","title":"Comparison of 2',3'-Dideoxyinosine (Didanosine, ddI) and Zidovudine in Therapy of Patients With the AIDS Dementia Complex","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"AIDS Dementia Complex, HIV Infections","enrollment":80},{"nctId":"NCT00000656","phase":"PHASE1","title":"A Phase I/II, Open Label Study to Evaluate the Antiviral Potential of Combination Zidovudine and 2' 3'-Dideoxyinosine (Didanosine) in Patients With Asymptomatic HIV Disease","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":116},{"nctId":"NCT00000637","phase":"PHASE3","title":"A Randomized Comparative Trial of Zidovudine (AZT) Versus 2',3'-Dideoxyinosine (ddI) Versus AZT Plus ddI in Symptomatic HIV-Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":819},{"nctId":"NCT00007202","phase":"PHASE2","title":"Safety and Effectiveness of a Three-Drug Combination Treatment for Recently Infected or Converted HIV Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":55},{"nctId":"NCT00008866","phase":"PHASE2","title":"Effectiveness of Early or Delayed Addition of Hydroxyurea to a Three-Drug Anti-HIV Drug Combination Including Didanosine, in Advanced HIV Patients Who Failed a First or Second Anti-HIV Triple-Drug Therapy","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00000963","phase":"PHASE2","title":"A Study of Dideoxyinosine (ddI) in HIV-Infected Children Who Have Not Had Success With Zidovudine or Who Cannot Take Zidovudine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00000954","phase":"PHASE1","title":"A Study of Chemotherapy Plus ddI or ddC in the Treatment of AIDS-Related Kaposi's Sarcoma","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Sarcoma, Kaposi, HIV Infections","enrollment":72},{"nctId":"NCT00928187","phase":"PHASE3","title":"Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2009-11","conditions":"HIV, HIV Infections","enrollment":454},{"nctId":"NCT00708162","phase":"PHASE3","title":"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-07","conditions":"HIV Infection","enrollment":724},{"nctId":"NCT01363011","phase":"PHASE3","title":"Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-05","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":106},{"nctId":"NCT00338390","phase":"PHASE3","title":"Study to Evaluate Changes in CD4 on Replacing TDF With ABC or DDI+TDF With ABC+3TC","status":"COMPLETED","sponsor":"Hospital de Granollers","startDate":"2005-04","conditions":"HIV Infections","enrollment":75},{"nctId":"NCT00364793","phase":"PHASE1, PHASE2","title":"Safety, Tolerability and Pharmacokinetics of Efavirenz in HIV-Infected Children","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-02","conditions":"HIV Infections","enrollment":56},{"nctId":"NCT00000922","phase":"NA","title":"A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":1710},{"nctId":"NCT00000652","phase":"PHASE1","title":"A Phase I Study to Evaluate the Safety and Toxicity of the Combination of Zidovudine and 2',3'-Dideoxyinosine (Didanosine) in Children With HIV Infection","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"","conditions":"HIV Infections","enrollment":85},{"nctId":"NCT00013520","phase":"PHASE3","title":"Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":1125},{"nctId":"NCT00002035","phase":"NA","title":"Double-Blind Comparison of the Efficacy of Continued Zidovudine Versus 2',3'-Dideoxyinosine (ddI) (BMY-40900) for the Treatment of Patients With AIDS or AIDS-Related Complex and Increasing Symptomatology Despite Treatment With Zidovudine","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00002280","phase":"NA","title":"A Study of ddI in Children With AIDS Who Have Not Had Success With Zidovudine","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00116415","phase":"NA","title":"DART I - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2002-03","conditions":"HIV Infections, AIDS","enrollment":65},{"nctId":"NCT00000672","phase":"PHASE2","title":"An Efficacy Study of 2',3'-Dideoxyinosine (ddI) (BMY-40900) Administered Orally Twice Daily to Zidovudine Intolerant Patients With AIDS or AIDS-Related Complex","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":660},{"nctId":"NCT00000979","phase":"PHASE2","title":"Comparison of ddI Versus Zidovudine in HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":1500},{"nctId":"NCT00000671","phase":"PHASE2","title":"A Phase II Efficacy Study Comparing 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine Therapy of Patients With HIV Infection Who Have Been on Long Term Zidovudine Treatment","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":750},{"nctId":"NCT00135382","phase":"PHASE3","title":"Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based Regimen","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2002-06","conditions":"HIV Infections","enrollment":254},{"nctId":"NCT00000669","phase":"PHASE1","title":"A Phase I Safety and Pharmacokinetics Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Infants and Children With AIDS or Symptomatic HIV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":25},{"nctId":"NCT00000971","phase":"PHASE1","title":"The Safety and Effectiveness of Clarithromycin Plus Zidovudine or Dideoxyinosine in the Treatment of Mycobacterium Avium Complex (MAC) Infections in Children With AIDS","status":"COMPLETED","sponsor":"Abbott","startDate":"","conditions":"Mycobacterium Avium-intracellulare Infection, HIV Infections","enrollment":24},{"nctId":"NCT00642291","phase":"PHASE2","title":"An Open-Label Study of Emtricitabine in Combination With Other Antiretroviral Agents in HIV Infected Pediatric Subjects","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2002-11","conditions":"HIV Infections","enrollment":16},{"nctId":"NCT00001267","phase":"PHASE3","title":"A Randomized Pilot Study for the Treatment of AIDS or AIDS Related Complex With an Alternating or Simultaneous Combination Regimen of AZT and 2',3'-Dideoxyinosine","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1990-10","conditions":"AIDS-Related Complex, Acquired Immunodeficiency Syndrome","enrollment":42},{"nctId":"NCT00002274","phase":"NA","title":"A Study of ddI in Patients With AIDS Who Become Sicker While Taking Zidovudine","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"","conditions":"HIV Infections, Leukoencephalopathy, Progressive Multifocal","enrollment":""},{"nctId":"NCT00002028","phase":"NA","title":"A Treatment IND (Investigational New Drug) Protocol for the Use of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS- Related Complex (ARC) Who Are Intolerant to Zidovudine (Retrovir)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00002407","phase":"NA","title":"A Study of Three Drug Combination Therapies in HIV-Infected Patients Who Have Never Been Treated With Anti-HIV Drugs","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00002014","phase":"PHASE1","title":"A Phase I Study to Evaluate the Pharmacokinetics, Safety and Antiviral Effects of Concurrent Administration of Zidovudine (AZT) and 2'3'-Dideoxyinosine (ddI) in Patients With Human Immunodeficiency Virus (HIV)","status":"COMPLETED","sponsor":"Glaxo Wellcome","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00002211","phase":"NA","title":"Safety and Effectiveness of Giving Combinations of Three or Four Anti-HIV Drugs to HIV-Infected Patients","status":"COMPLETED","sponsor":"Pharmacia and Upjohn","startDate":"","conditions":"HIV Infections","enrollment":160},{"nctId":"NCT00001997","phase":"NA","title":"Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine or Dideoxyinosine in HIV Positive, Asymptomatic and Symptomatic Individuals","status":"COMPLETED","sponsor":"Chiron Corporation","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00002001","phase":"NA","title":"The Antiviral Efficacy of Concurrent Zidovudine and 2',3'-Dideoxyinosine or 2',3'-Dideoxycytidine in Patients With Human Immunodeficiency Virus Disease","status":"COMPLETED","sponsor":"Glaxo Wellcome","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00002099","phase":"PHASE2","title":"Phase II/III Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients","status":"UNKNOWN","sponsor":"AJI Pharma USA","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00002098","phase":"PHASE1","title":"Phase I/II Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients","status":"COMPLETED","sponsor":"AJI Pharma USA","startDate":"","conditions":"HIV Infections","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"2',3'-dideoxyinosine","genericName":"2',3'-dideoxyinosine","companyName":"National Cancer Institute (NCI)","companyId":"national-cancer-institute-nci","modality":"Small molecule","firstApprovalDate":"","aiSummary":"2',3'-dideoxyinosine (ddI) is a nucleoside reverse transcriptase inhibitor that blocks HIV replication by inhibiting the enzyme responsible for converting viral RNA into DNA. Used for HIV-1 infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}